抗逆转录病毒药物的现状与研发  

Current situation and study development on anti-retroviral drugs

作　　者：单晓蕾 付淑军 孙涛[1] SHAN Xiaolei;FU Shujun;SUN Tao(Center for Drug Evaluation, National Medical Products Administration, Beijing 100022, China)

机构地区：[1]国家药品监督管理局药品审评中心

出　　处：《药物评价研究》2019年第7期1442-1447,共6页Drug Evaluation Research

摘　　要：获得性免疫缺陷综合征(AIDS)是威胁人类健康的最危险疾病之一,是由人免疫缺陷病毒(HIV-1)感染引起。从HIV-1病毒发现后的30余年,已有大量的抗逆转录病毒药物投入研发,抑制病毒复制增殖周期的关键阶段。抗逆转录病毒药物延长了患者生命,同时也产生了病毒的耐药变异,因此需要开发针对耐药的新药物。简述美国已上市的抗逆转录病毒药物信息,重点关注抗逆转录病毒药物的研发进展以及非临床研究中的相关问题。The human immunodeficiency virus type 1 (HIV-1) is the causative agent of one of the most dangeroushuman diseases - the acquired immune deficiency syndrome (AIDS).Over the past 30 years since thediscovery of HIV-1,a number of antiviral drugs have been developed to suppress various stages of the HIV-1 lifecycle.This approach has enabled the suppression of virus replication in the body,which significantly prolongs the life of HIV patients.The main downside of the method is the development of viral resistance to many anti-HIV drugs,which requires the creation of new drugs against drug-resistant viral forms effectively.This review summarizes current information on antiviral drugs in the US and focuses on the development and the nonclinical study concerns for antiviral drugs.

关 键 词：抗逆转录病毒药物 HIV-1 非临床研究 获得性免疫缺陷综合征 

分 类 号：R978.7[医药卫生—药品]